학술논문
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study
Document Type
Article
Author
Chesney, J.; Egger, M.E.; Lewis, K.D.; Medina, T.; Kluger, H.; Hamid, O.; Whitman, E.; Thomas, S.; Wermke, M.; Cusnir, M.; Domingo-Musibay, E.; Phan, G.Q.; Kirkwood, J.M.; Hassel, J.C.; Orloff, M.; Larkin, J.; Furness, A.J.S.; Weber, J.; Khushalani, N.I.; Sarnaik, A.; Graf Finckenstein, F.; Jagasia, M.; Hari, P.; Sulur, G.; Shi, W.; Wu, X.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 13 December 2022, 10(12))
Subject
Language
English
ISSN
20511426